$AMD

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Dynatrace, Five Below, Fortune Brands, Klarna Group, Jersey Mike’s Subs, Moderna, Sherwin-Williams, and More

Wall Street analysts issued updates on several companies. AMD was upgraded to Strong Buy with a $641 target, while Five Below was downgraded to Hold. Bitcoin continued its rally, trading near $79,420. Investors await Fed comments and inflation data.

Original reporting
Published Aug 25, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 2:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Dynatrace, Five Below, Fortune Brands, Klarna Group, Jersey Mike’s Subs, Moderna, Sherwin-Williams, and More — source image
Decision brief

The 30-second read

$AMDBullishMed
01

Why it matters

Collective analyst rating changes provide fresh signals for short-term positioning, though overall market sentiment remains mixed ahead of Fed commentary.

02

Market read

Analyst rating shifts can trigger immediate price moves, especially for high‑profile names like AMD and SHW.

03

What to watch

Potential macro headwinds from upcoming Fed data could dampen enthusiasm despite upgrades.

Relevance 5/10Novelty 5/10Timing: today

Background

Daily analyst research roundup highlighting upgrades, downgrades, and initiations across various US-listed stocks.

Company-level read

Ticker impact

$AMDBullishMedium confidence
Context

Upgraded to Strong Buy from Outperform with price target raised to $641.

Expected impact

Potential short-term upside of 3-5% on news flow.

Evidence & confidence

Upgrade from a reputable house with a higher target suggests near-term buying pressure.

$BFHBullishMedium confidence
Context

Upgraded to Outperform from Peer Perform with $130 target.

Expected impact

Modest upside of 1-2% expected.

Evidence & confidence

Target increase modest; market may price in gradually.

$DTBullishMedium confidence
Context

Upgraded to Overweight from Equal Weight, target raised to $65.

Expected impact

Potential 2-4% rally.

Evidence & confidence

Higher weight and target suggest bullish sentiment.

$MRNABullishLow confidence
Context

Raised to Peer Perform from Underperform, no target change.

Expected impact

Limited upside, 1-2% move.

Evidence & confidence

Rating lift without target indicates modest sentiment shift.

$FOURBullishMedium confidence
Context

Upgraded to Overweight from Equal Weight, target $59.

Expected impact

Potential 2-3% gain.

Evidence & confidence

Higher weight and target may attract short-term buying.

$FISBearishMedium confidence
Context

Downgraded to Equal Weight from Overweight, target $46.

Expected impact

Possible 2-4% decline.

Evidence & confidence

Downgrade suggests weaker expectations.

$FIVEBearishLow confidence
Context

Downgraded to Hold from Buy, target unchanged at $250.

Expected impact

Minor downside pressure.

Evidence & confidence

Hold rating may temper momentum.

$KLARBearishLow confidence
Context

Downgraded to Peer Perform from Outperform, no target.

Expected impact

Potential modest pullback.

Evidence & confidence

Rating cut without target suggests limited impact.

Market effects

Broad analyst activity may lift sentiment across tech, fintech, and consumer discretionary sectors.

US market focus; limited direct regional effect.

Minor global impact; primarily US equity investors.

Counterpoint

Some upgrades may be premature given macro uncertainty; caution on short-term trades.

Key entities

  • Raymond James

    Upgraded AMD to Strong Buy.

  • Wolfe Research

    Provided multiple upgrades/downgrades.

  • Morgan Stanley

    Upgraded Dynatrace.

Related articles

$AMDMed

Samsung sets record Q3 earnings with Korea’s first-ever quarterly profit above 100 trillion won

Samsung Electronics reported record Q3 earnings, exceeding 100 trillion won. The company passed qualification tests for HBM4E chips with Nvidia and major hyperscalers. Samsung also agreed to supply HBM4 chips to AMD and plans to increase HBM4 DRAM output capacity by 70% to meet rising demand from Nvidia and AMD. According to the company, this expansion supports its focus on AI semiconductors.

$AMDMed

AMD's Lisa Su Favors Samsung Over SK hynix in Seoul Visit

AMD's Lisa Su met with Samsung Electronics' semiconductor head to discuss AI cooperation, including HBM4 supplies for AMD's Instinct MI455X chip. The long meeting suggests Samsung may gain an advantage over SK hynix in memory cooperation with AMD. Samsung was previously chosen as the first HBM4 supplier for AMD's next-gen chip.

$AMDHighAI 9/10

Is Advanced Micro Devices Inc. (AMD) Right to Bet $8.2 Billion on the Future of Physical AI?

Advanced Micro Devices (AMD) acquired World Labs for $8.2B to strengthen its AI hardware and software development. World Labs specializes in 3D AI models for robotics and autonomous machines. The deal aims to position AMD in physical AI, expanding its market beyond generative AI. AMD expects to optimize its Instinct GPUs and infrastructure for emerging workloads. The all-stock transaction may dilute AMD's shares.

$MRNAHigh

MRNA Jumps As Nasdaq-100 Inclusion And Cancer Pipeline Shift Momentum

Moderna Inc. (MRNA) shares rose 4.78% on October 7, 2026, driven by positive mRNA pipeline data and upcoming inclusion in the Nasdaq-100 index. The company reported quarterly revenue of $1.92B, but with significant losses. Traders are watching MRNA for its potential as a growth platform with catalysts like the index inclusion and cancer vaccine developments.

$MRNAHighAI 8/10

MRNA Stock Jumps As Nasdaq-100 Inclusion Ignites Momentum

Moderna Inc. (MRNA) stock rose 4.82% after being added to the Nasdaq-100 index. The company reported a net loss of $782M but has strong cash reserves. Positive data for its cancer vaccine and a new COO appointment also influenced trading. MRNA's stock has been volatile, with a recent uptrend and a 6-7% drop on the management change news.